/
and Overview of Business ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications. Our team is focused on providing quality, innovation and value to our clinical customers worldwide.
Operating margin is thin at 4.90%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 6.3% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 26% versus the prior year, cash generation momentum has weakened. Net debt of $1.04B represents 11.3x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$2.16B
▼ -6.3% YoY
Net Income (TTM)
$46M
▲ +100.6% YoY
Op. Margin
5.10%
▲ +3.1pp YoY
ROIC
2.49%
▲ +2.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$83M
▼ -26.4% YoY
Op. Cash Flow (TTM)
$167M
▼ -11.9% YoY
Net Debt
$1.05B
Cash & Equiv.
$288M
5Y CAGR: +11.9%
5Y CAGR: -6.8%
Continue Research